Rennan Mano flag Denunciar. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. Libby P. Inflammation in atherosclerosis.
|Published (Last):||9 August 2016|
|PDF File Size:||17.28 Mb|
|ePub File Size:||1.36 Mb|
|Price:||Free* [*Free Regsitration Required]|
Figura 1. The atherogenic dyslipidemia in synergy with metabolic disorders such as diabetes mellitus type 2, metabolic syndrome, hypertension and obesity, added to other factors such as smoking, diet and stress is associated with cardiovascular diseases. Although the impact of changes in lipid metabolism in this process is established by a high concentrations of CT, triglycerides and LDL-C, and decreased HDL-C, the effects of these changes in the homeostasis have not been fully elucidated, the effects of changes in the homeostasis have not been fully elucidated, limiting clinical and therapeutic improvements.
In the present work a non-systematic review about the possible changes associated with atherogenic dyslipidemia currently described in the literature, which allowed a summarization of the findings described so far.
In the present study, a non-systematic review of possible changes in the homeostasis associated with atherogenic dyslipidemia currently described in the literature was made, which allowed a summarization of the mechanisms described so far.
Palavras-chave Aterosclerose. Abstract The atherogenic dyslipidemia in synergy with metabolic disorders such as diabetes mellitus type 2, metabolic syndrome, hypertension and obesity, added to other factors such as smoking, diet and stress is associated with cardiovascular diseases.
Keywords Atherosclerosis; Dyslipidemias; Homeostasis; Lipoproteins. Elsevier; In: Arquivos Brasileiros de Cardiologia. Sociedade Brasileira de Cardiologia; Plasma lipoproteins: apolipoprotein structure and function.
J Lipid Res. Clin Chem. Arq Bras Cardiol. Forti N, Diament J. Apolipoprotein B and A-I: cardiovascular risk factor? Rev Assoc Med Bras Perdomo G, Henry Dong H. Apolipoprotein D in lipid metabolism and its functional implication in atherosclerosis and aging.
Aging Albany NY. Apolipoprotein E and atherosclerosis: insight from animal and human studies. Clin Chim Acta. Phillips MC. Apolipoprotein E isoforms and lipoprotein metabolism. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J Biol Chem. Apolipoprotein E polymorphism and atherosclerosis: insight from a study in octogenarians.
Trans Am Clin Climatol Assoc. Pre-diabetes in overweight youth and early atherogenic risk. Metabolic syndrome: identifying the risk factors. J Pediatr Rio J. Insulin resistance and components of metabolic syndrome, analysis by gender and stage of adolescence.
Arq Bras Endocrinol Metabol. Jorge PA. Endothelium, lipids and atherosclerosis. Med Clin Barc. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk.
J Clin Endocrinol Metab. The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma.
Human retrovirus-5 in rheumatic disease. J Autoimmun [Internet]. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance.
Alterations in Thrombosis and Fibrinolysis in the Metabolic Syndrome. Rev Bras Hematol Hemoter.